An interventional study of Subacromial Triamcinolone Acetonide Injection and Intramuscular Saline Placebo Injection in Supraspinatus Tendinopathy, sponsored by Dr.Rumeysa Türkoğlu. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Dr.Rumeysa Türkoğlu · Not applicable, Interventional, and Treatment
This prospective, randomized, double-blind, placebo-controlled clinical trial evaluates the effects of a subacromial corticosteroid injection combined with a 12-week home-based exercise program in patients aged 18 to 60 years with supraspinatus tendinopathy. A total of 56 participants will be randomized into two groups. The intervention group will receive an ultrasound-guided subacromial-subdeltoid injection of 20 mg triamcinolone acetonide plus saline, while the placebo group will receive an ultrasound-guided intramuscular saline injection into the deltoid. Both groups will follow the same 12-week exercise program. The primary outcome is the change in supraspinatus tendon elasticity measured by shear wave elastography. Secondary outcomes include pain, shoulder function, disability, and quality of life assessed using VAS, Constant-Murley Score, QuickDASH, SPADI, and SF-12.
Participants who meet the eligibility criteria and provide written informed consent will be randomized using a computer-based block randomization method. The corticosteroid group will receive an ultrasound-guided injection of 20 mg triamcinolone acetonide (1 mL) plus 1 mL saline into the subacromial-subdeltoid bursa. The placebo group will receive an equal volume of 0.9% saline administered intramuscularly into the deltoid under ultrasound guidance.
Following the injection, participants in both groups will begin the same 12-week home-based exercise program, performed three days per week for approximately 30-40 minutes per session. The program includes warm-up, scapular stabilization, rotator cuff strengthening, eccentric exercises, stretching, and mobility exercises, with progression according to pain level, muscle control, and exercise technique.
Shear wave elastography measurements of the supraspinatus tendon will be performed at baseline and at week 12. Clinical assessments, including VAS, SF-12, Constant-Murley Score, QuickDASH, and SPADI, will be performed at baseline, week 6, and week 12. The study aims to determine whether the addition of subacromial corticosteroid injection to exercise alters tendon elasticity and clinical outcomes compared with placebo injection plus exercise.
397 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.
This study's planned enrollment of 56 is above the median of 48 across 332 interventional studies indexed under Tendinopathy.
Browse Tendinopathy studies →This is the only study on the registry with Dr.Rumeysa Türkoğlu as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive an ultrasound-guided injection of 20 mg triamcinolone acetonide (1 mL) plus 1 mL saline into the subacromial-subdeltoid bursa. Following the injection, participants will begin a 12-week home-based exercise program performed 3 days per week.
Drug: Subacromial Triamcinolone Acetonide Injection · Behavioral: Home-Based Exercise Program
Participants will receive an equal volume of 0.9% saline administered intramuscularly into the deltoid under ultrasound guidance. Following the injection, participants will begin the same 12-week home-based exercise program performed 3 days per week.
Drug: Intramuscular Saline Placebo Injection · Behavioral: Home-Based Exercise Program
A single ultrasound-guided injection of 20 mg triamcinolone acetonide (1 mL) plus 1 mL saline into the subacromial-subdeltoid bursa.
An equal volume of 0.9% saline administered as a single ultrasound-guided intramuscular injection into the deltoid.
A 12-week home-based exercise program performed 3 days per week for approximately 30-40 minutes per session. The program includes warm-up, scapular stabilization, rotator cuff strengthening, eccentric exercises, stretching, and mobility exercises
Change in Supraspinatus Tendon Elasticity Measured by Shear Wave Elastography
Supraspinatus tendon elasticity will be assessed using shear wave elastography (SWE). Measurements will be obtained from the tendon footprint and mid-substance regions, with at least three measurements taken from each region and the median value recorded. The change in tendon elasticity from baseline to week 12 will be evaluated.
Time frame: Baseline and Week 12
Change in Shoulder Pain Measured by Visual Analog Scale (VAS)
Shoulder pain will be assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Rest pain, activity-related pain, and night pain will be recorded separately. Higher scores indicate greater pain severity.
Time frame: Baseline, Week 6, and Week 12
Change in Shoulder Function Measured by Constant-Murley Score
Shoulder function will be assessed using the Constant-Murley Score, ranging from 0 to 100 points. The score evaluates pain, activities of daily living, range of motion, and strength. Higher scores indicate better shoulder function
Time frame: Baseline, Week 6, and Week 12
Change in Upper Extremity Disability Measured by QuickDASH
Upper extremity disability will be assessed using the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire, scored from 0 to 100. Higher scores indicate greater disability and poorer upper extremity function.
Time frame: Baseline, Week 6, and Week 12
Change in Shoulder Pain and Disability Measured by SPADI
Shoulder pain and disability will be assessed using the Shoulder Pain and Disability Index (SPADI), scored from 0 to 100. The scale includes pain and disability subscales. Higher scores indicate greater pain and disability.
Time frame: Baseline, Week 6, and Week 12
Change in Health-Related Quality of Life Measured by SF-12
Health-related quality of life will be assessed using the 12-Item Short Form Health Survey (SF-12). The SF-12 provides a Physical Component Summary (PCS-12) score and a Mental Component Summary (MCS-12) score, each ranging from 0 to 100. Higher scores indicate better health status and health-related quality of life.
Time frame: Baseline, Week 6, and Week 12
Plan to share: No — Individual participant data will not be shared because no data-sharing plan was specified in the approved study protocol.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.
Of 174 non-industry interventional studies with no phase under Tendinopathy, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 4 months is below that.
Counting every sponsor, half of 183 studies reached it within 20 months; a quarter within 7 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.